Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

Conditions:   Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8;   Pathologic Stage IV HPV-Mediated (p16-Positive ) Oropharyngeal Carcinoma AJCC v8;   Recurrent Head and Neck Squamous Cell Carcinoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Oral Cavity Squamous Cell Carcinoma;   Recurrent Oropharyngeal Squamous Cell  Carcinoma;   Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage III Hypopharyngeal Carcinoma AJCC v8;   Stage III Laryngeal Cancer AJCC v8;   Stage III Lip and Oral Cavity Cancer AJCC v8;   Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8;   Stage IV Hypopharyngeal Carcinoma AJCC v8;   Stage IV Laryngeal Cancer AJCC v8;   Stage IV Lip and Oral Cavity Cancer AJCC v8;   Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage  IVA Hypopharyngeal Carcinoma AJCC v8;   Stage IVA Laryngeal Cancer AJCC v8;   Stage IVA Lip and Oral Cavity Cancer AJCC v8;   Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8;   Stage IVB Hypopharyngeal Carcinoma AJCC v8;   Stage IVB Laryngeal Canc...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials